Bibliography
- Kontzias A, Kotlyar A, Laurence A, et al. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 2012;12(4):464-70
- Menet CJ, Rompaey LV, Geney R. Advances in the discovery of selective JAK inhibitors. Prog Med Chem 2013;52:153-223
- Kiss R, Sayeski PP, Keserũ GM. Recent developments on JAK2 inhibitors: a patent review. Expert Opin Ther Pat 2010;20(4):471-95
- Wilson LJ. Recent patents in the discovery of small molecule inhibitors of JAK3. Expert Opin Ther Pat 2010;20(5):609-23
- Dymock BW, See CS. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012. Expert Opin Ther Pat 2013;23(4):449-501
- Norman P. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents. Expert Opin Ther Pat 2012;22(10):1233-49
- F Hoffman-La-Roche AG. Imidazopyridine compounds, compositions and methods of use. WO041539; 2013
- Liang J, Tsui V, Van Abbema A, et al. Lead identification of novel and selective TYK2 inhibitors. Eur J Med Chem 2013;67:175-87
- Liang J, van Abbema A, Balazs M, et al. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. J Med Chem 2013;56(11):4521-36
- Sohn SJ, Barrett K, Van Abbema A, et al. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol 2013;191(5):2205-16
- Argiriadi MA, Goedken ER, Banach D, et al. Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor. BMC Struct Biol 2012;12:22
- Sareum Ltd. Tyk2 kinase inhibitors. EP2634185; 2013
- Takeda Pharmaceutical Co. Ltd. Heterocyclic compound. WO125543; 2013
- Takeda Pharmaceutical Co. Ltd. Heterocyclic compound. WO2013146963; 2013
- Sareum Ltd. Oxazole Tyrosine Kinase Inhibitors. WO139161; 2008
- Sareum Ltd. Pharmaceutical compounds. WO055304; 2010
- Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and medicine. US20110288065A1; 2011
- Palau Pharma. Pyrrolopyrimidine derivatives as JAK3 inhibitors. WO119792; 2008
- Sareum Holdings plc. SAREUM and SRI international announce agreement to advance development of tyrosine kinase 2 inhibitors for treatment of autoimmune and inflammatory diseases. Press Release 22 April 2013 Available from: http://www.sareum.co.uk/pressreleases.php?newsid=185&year=-1
- Sareum Ltd. Tyk2 kinase program. 2013. Available from: http://www.sareum.co.uk/base/images/pdfs/Sareum_SKIL_TYK2_Jul13.pdf